Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs

Al Hammadi, Anwar; Parmar, Nisha V.; Aljefri, Khadija; Al Sharif, Osama; Abdallah, Marwa; Ahmed, Haytham Mohamed; Ammoury, Alfred

doi:10.1007/s13555-023-00946-8

Cited by 3 publications

(1 citation statement)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Unfortunately, the etiology of AA is still not well known. 5 Genetic predisposition, environmental triggers, and altered inflammatory responses have been cited as components involved in AA. 6 Social factors such as stress were previously thought to be instigators as well.…”

Section: Introductionmentioning

confidence: 99%

A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system

Ravipati,

Pradeep,

Tosti

2024

Int J Dermatology

View full text Add to dashboard Cite

BackgroundAlopecia areata (AA) is an autoimmune condition that leads to patchy, nonscarring hair loss. Its etiology remains unknown; the condition can be debilitating for patients, impacting their psychosocial wellbeing. Various triggers have been reported, ranging from genetic predisposition and infections to environmental factors. Medications have also been thought to be an inciting factor in AA.MethodsUsing the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS), all cases reporting AA as an adverse event were used to capture associated medications and patient characteristics.ResultsThere were 1,331 AA cases reported as an adverse event with medication use. Monoclonal antibodies accounted for 6 out of the top 10 drugs associated with the highest number of AA cases. Males were more likely to report AA when taking adalimumab (OR: 1.79, P = 0.04) and dupilumab (OR: 2.56, P = 0.03) compared to females. Individuals between 42 and 64 years old accounted for 46.7% of AA cases. Lastly, females in older age groups showed greater odds of developing AA compared to males (OR: 1.03, P < 0.01).ConclusionsBased on the FAERS, there has been a steady rise in AA cases, and monoclonal antibodies were the most frequently cited medication class tied to AA. With a dearth of literature on triggers and patient demographics, we sought to describe features of AA cases that could increase awareness and be used to improve future clinical outcomes in patients.

show abstract

Section: Introductionmentioning

confidence: 99%

A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system

Ravipati,

Pradeep,

Tosti

2024

Int J Dermatology

View full text Add to dashboard Cite

show abstract

Global, regional and national epidemiology of alopecia areata: a systematic review and modelling study

Jeon,

Jung,

Kim

et al. 2024

British Journal of Dermatology

View full text Add to dashboard Cite

Background Alopecia areata (AA) is a chronic autoimmune disease that leads to a high psychiatric, economic, and systemic disease burden. A comprehensive understanding of AA epidemiology is essential for evaluating healthcare source utilization; however, there is a lack of systematic approach for summarizing epidemiologic data on AA. Objectives To systematically investigate the global, regional, and national incidence and prevalence of AA. Methods A structured search was conducted using the Ovid MEDLINE, EMBASE, Cochrane Library, Web of Science, SciELO, and Korean journal databases from their inception date to October 4, 2023. Studies that reported the prevalence or incidence of AA were included. We used a Bayesian hierarchical linear mixed model to analyse the prevalence estimates. The primary outcomes of our study were the global, regional, and national prevalence of physician-diagnosed AA for overall population, adults, and children. The incidence data were summarised descriptively. Results In total, 88 studies from 28 countries were included in the analysis. The reported incidence of alopecia areata tended to be higher in adults aged 19–50 years, and this trend was consistent with its estimated prevalence. The reported prevalence in overall population tended to be higher in men compared to in women. The estimated lifetime prevalence of AA was 0.10% (95% credible intervals, 0.03%–0.39%) in the general population worldwide, 0.12% (95% credible intervals, 0.02%–0.52%) in adults, and 0.03% (95% credible intervals, 0.01%–0.12%) in children. The estimated prevalence was highest in the Asian region and lowest in the African region. Conclusions In this study, 48% of the total Global Burden of Disease regions had insufficient data reporting the prevalence or incidence of AA. Further studies are needed to provide epidemiological information on middle- and low-income countries. Our study can serve as a crucial reference in terms of healthcare policy decisions.

show abstract

The demographic and clinical profile of patients with alopecia areata in Syria: A study letter

Al-Dabbagh,

Sliman,

Hanino

et al. 2024

CSDM

View full text Add to dashboard Cite

Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs

Cited by 3 publications

References 99 publications

A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system

A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system

Global, regional and national epidemiology of alopecia areata: a systematic review and modelling study

The demographic and clinical profile of patients with alopecia areata in Syria: A study letter

Contact Info

Product

Resources

About